Purdue researchers apply new technique to manipulate virus, make it a possible cancer treatment
November 27, 2013
WEST LAFAYETTE, Ind. — Purdue University researchers successfully eliminated the native infection preferences of a Sindbis virus engineered to target and kill cancer cells, a milestone in the manipulation of this promising viral vector.
"This virus had been known to be a good vector for delivering therapeutic cargo, however it naturally infected all kinds of cells, and these diversions would compete with what we were instructing it to target," said Richard Kuhn, the Gerald and Edna Mann Director of Purdue's Bindley Biosciences Center. "We have now overcome a major challenge by not only inserting a targeting molecule of our choice, but also successfully stripping the virus of its native entry preferences. This was a big step in unlocking the potential of developing this virus into a platform for both targeted drug delivery, where it would sneak drugs inside cancer cells, and oncolytic virotherapy, where the virus itself destroys cancer cells."
- Elizabeth K. Gardner, Writer
September 5, 2014
Purdue University marked the opening of new Discovery Park interdisciplinary research facilities in drug development and cancer, key components of the Purdue Moves initiative, during a dedication ceremony on Friday (Sept. 5).Read Full Story
September 3, 2014
Purdue University is planning a ceremony to mark the opening of a nearly $29 million facility that will consolidate drug research centers at the school and a $16 million expansion of a cancer research center.Read Full Story
July 9, 2014
Moments after Dr. Jeff Crecelius completes a surgery, hopeful family members typically want to know if he was able to "get it all," or remove all of the cancerous tumor from the brain of a loved one. It's their emotional plea for reassurance. They want to know that the ordeal is completed and that the brain tumor has met its match — the hands of a skilled surgeon.Read Full Story